Talphera (TLPH) Non-Current Assets (2010 - 2026)
Talphera (TLPH) posted Non-Current Assets of $8.8 million for Q2 2026, little changed on a QoQ basis from $8.8 million in Q1 2026, and little changed year-over-year from $8.8 million in Q2 2025.
Analysis
Talphera (TLPH) Non-Current Assets (2010 - 2026) Analysis & Trends
Talphera has reported Non-Current Assets for 17 years, with the latest figure at $8.8 million in Q2 2026.
- On a quarterly basis, Non-Current Assets changed 0.0% year-over-year to $8.8 million in Q2 2026; TTM through Jun 2026 was $35.3 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $8.8 million, changed 0.0% from the prior year.
- Non-Current Assets was $8.8 million for Q2 2026 at Talphera, roughly flat from $8.8 million in the prior quarter.
- The five-year high for Non-Current Assets was $29.2 million in Q1 2022, with the low at $8.8 million in Q4 2023.
- Average Non-Current Assets over 5 years is $12.4 million, with a median of $8.8 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets surged 81.89% in 2022, then slumped 69.35% in 2023.
- Over 5 years, Non-Current Assets stood at $22.9 million in 2022, then tumbled by 61.52% to $8.8 million in 2023, then changed by 0.0% to $8.8 million in 2024, then changed by 0.0% to $8.8 million in 2025, then changed by 0.0% to $8.8 million in 2026.
- The last three Non-Current Assets figures came in at $8.8 million (Q2 2026), $8.8 million (Q1 2026), and $8.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 564.41 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - | 8.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.82 Mn |
| Mar 31, 2026 | 8.82 Mn |
| Dec 31, 2025 | 8.82 Mn |
| Sep 30, 2025 | 8.82 Mn |
| Jun 30, 2025 | 8.82 Mn |
| Mar 31, 2025 | 8.82 Mn |
| Dec 31, 2024 | 8.82 Mn |
| Sep 30, 2024 | 8.82 Mn |
| Jun 30, 2024 | 8.82 Mn |
| Mar 31, 2024 | 8.82 Mn |
| Dec 31, 2023 | 8.82 Mn |
| Sep 30, 2023 | 8.84 Mn |
| Jun 30, 2023 | 8.89 Mn |
| Mar 31, 2023 | 8.94 Mn |
| Dec 31, 2022 | 22.92 Mn |
| Sep 30, 2022 | 23.77 Mn |
| Jun 30, 2022 | 24.14 Mn |
| Mar 31, 2022 | 29.16 Mn |
| Dec 31, 2021 | 27.40 Mn |
| Sep 30, 2021 | 20.51 Mn |